Epcoritamab (Epcor)-Containing Combination Salvage Therapy Followed by ASCT & Epcor Consolidation in Patients With Relapsed LBCL

Conditions: DLBCL - Diffuse Large B Cell Lymphoma; High-grade B-cell Lymphoma; High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements; DLBCL, Nos Genetic Subtypes; High Grade B-Cell Lymphoma, Not Otherwise Specified; Follicular Large Cell Lymphoma, Relapsed; Follicular Large Cell Lymphoma Interventions: Drug: Epcoritamab Sponsors: Australasian Leukaemia and Lymphoma Group Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials